



08-10-06

CASE 1-32642A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

21731066425 US
Express Mail Label Number

August 8, 2006
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
CIVENNI ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/10469

FILED: 19 SEPTEMBER 2003

U.S. APPLICATION NO: 10/528,439

35 USC §371 DATE: 18 MARCH 2005

FOR: WNT MEDIATED ERBB SIGNALLING, COMPOSITIONS AND USES
RELATED THERETO

MS: AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the restriction requirement of May 8, 2006, Applicants hereby elect Group I, claims 1-10 and 17-19, drawn a method for inhibiting EGF receptor signaling in vitro, said method comprising contacting a cell having EGF receptors and Frizzled (Fz) at the cell surface with a Wnt antagonist in a sufficient amount to reduce the EGF receptor and a kit for detecting Erb signaling. Applicants hereby also elect Wnt1 with respect to claim 1, and Wnt and Fz with respect to claim 17.

Applicants have enclosed herewith a petition for two month extension of time. Applicants believe that no fees are due with this filing. However, if it is deemed that additional fees are required, the Commissioner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis for any fees due. An early and favorable action on the merits is respectfully requested.

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3343
Dated: August 8, 2006

Respectfully submitted,


Paul J. Paglierani
Attorney for Applicants
Reg. No. 52,498